KGX105 / KangaBio - LARVOL DELTA

Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=85 | Not yet recruiting | Sponsor: Kangabio AUSTRALIA LTD PTY

First-in-human • New P1 trial • Oncology • Solid Tumor

KGX105, a conditionally active prodrug of EGFRxCD3 T cell engager induces anti-tumor potency (AACR 2025) - "The pilot toxic study to evaluate the safety and toxicokinetics of KGX105 is ongoing in Cynomolgus monkeys. The studies presented herein support KGX105 as a promising novel therapeutic to target a wide range of EGFR-expressing cancers with the potential to avoid the life-threatening on-target toxicities and systemic cytokine release."

Colorectal Cancer • Hematological Malignancies • Oncology • Solid Tumor